Universität zu Köln

Soumerai, Jacob D., Ni, Ai ORCID: 0000-0003-3002-3556, Xing, Guan, Huang, Julie, Furman, Richard R., Jones, Jeffrey, Sharman, Jeffrey P., Hallek, Michael, Adewoye, Adeboye H., Dubowy, Ronald, Dreiling, Lyndah and Zelenetz, Andrew D. (2019). Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk. Lymphoma, 60 (6). S. 1438 - 1447. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

The CLL-IPI is a risk-weighted prognostic model for previously untreated patients with chronic lymphocytic leukemia (CLL), but has not been evaluated in patients with relapsed CLL or on novel therapies. We evaluated the CLL-IPI in 897 patients with relapsed/refractory CLL in 3 randomized trials testing idelalisib (PI3K inhibitor). The CLL-IPI identified patients as low (2.2%), intermediate (12.8%), high (48.7%), and very high (36.2%) risk and was prognostic for survival (log-rank p<.0001; C-statistic 0.706). Of CLL-IPI factors, age >65, 2-microglobulin >3.5mg/L, unmutated immunoglobulin heavy chain variable region gene, and deletion 17p/TP53 mutation were independently prognostic, but Rai I-IV or Binet B/C was not. The CLL-IPI is prognostic for survival in relapsed CLL and with idelalisib therapy. However, low/intermediate risk is uncommon, and regression parameters of individual factors in this risk-weighted model appear different in relapsed CLL. Reassessment of the weighting of the individual variables might optimize the model in this setting.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Soumerai, Jacob D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ni, Ai UNSPECIFIED orcid.org/0000-0003-3002-3556 UNSPECIFIED Xing, Guan UNSPECIFIED UNSPECIFIED UNSPECIFIED Huang, Julie UNSPECIFIED UNSPECIFIED UNSPECIFIED Furman, Richard R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Jones, Jeffrey UNSPECIFIED UNSPECIFIED UNSPECIFIED Sharman, Jeffrey P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Adewoye, Adeboye H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Dubowy, Ronald UNSPECIFIED UNSPECIFIED UNSPECIFIED Dreiling, Lyndah UNSPECIFIED UNSPECIFIED UNSPECIFIED Zelenetz, Andrew D. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-148327
DOI:	10.1080/10428194.2018.1540782
Journal or Publication Title:	Leuk. Lymphoma
Volume:	60
Number:	6
Page Range:	S. 1438 - 1447
Date:	2019
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1029-2403
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GENE MUTATION STATUS; GENOMIC ABERRATIONS; ZAP-70 EXPRESSION; CD38 EXPRESSION; SURVIVAL; COMBINATION; OFATUMUMAB; PREDICTOR; RITUXIMAB; IBRUTINIB Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14832